Further, IMP2-regulated RNAs present a clear target for immuno-oncology, while pharmacological inhibition of IMP2 is emerging as a strategy to mitigate the myriad effects of this versatile RNA-binding protein—particularly as a regulator of type 2 diabetes and as a cancer-promoting oncoprotein that governs a broad spectrum of oncogenic RNAs. This evidence concerns the gene IGF2BP2 and type 2 diabetes mellitus.